Sartorius: UBS upgrades to 'buy'
(CercleFinance.com) - UBS has upgraded its rating on the Sartorius stock from "neutral" to "buy," while maintaining its target price at 142 euros, which suggests upside potential of 23% for the German pharmaceutical and laboratory equipment supplier.
The broker says that "Sartorius can deliver supernormal growth on the back of its Bioprocess Solutions business BPS (73% of sales)", It adds that the group's targets for 2018 and 2020 are not at risk, despite soft Q3 results for the other parts of the top-line (Lab Products and Services, LPS).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The broker says that "Sartorius can deliver supernormal growth on the back of its Bioprocess Solutions business BPS (73% of sales)", It adds that the group's targets for 2018 and 2020 are not at risk, despite soft Q3 results for the other parts of the top-line (Lab Products and Services, LPS).
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.